Drug–drug interactions in the metabolism of imidafenacin: Role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes

References

• Bourrie M, Meunier V, Berger Y, F1abre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 1996; 277: 321–332
   PubMed Web of Science ®Google Scholar
• Burke MD, Prough RA, Mayer RT. Characteristics of a microsomal cytochrome P-448-mediated reaction. Ethoxyresorufin O-de-ethylation. Drug Metabolism and Disposition 1997; 5: 1–8
   Google Scholar
• Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochemical Pharmacology 1985; 34: 3337–3345
   PubMed Web of Science ®Google Scholar
• Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochemical Pharmacology 1994; 48: 923–936
   PubMed Web of Science ®Google Scholar
• Chang TK, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics 1994; 11: 437–442
   Web of Science ®Google Scholar
• Chiu SH, Huskey SW. Species differences in N-glucuronidation. Drug Metabolism and Disposition 1998; 26: 838–847
   PubMed Web of Science ®Google Scholar
• Dixon M. The determination of enzyme inhibitor constants. Biochemical Journal 1953; 55: 161–170
   PubMed Web of Science ®Google Scholar
• Doherty MM, Charman WN. The mucosa of the small intestine: How clinically relevant as an organ of drug metabolism?. Clinical Pharmacokinetics 2002; 41: 235–253
   PubMed Web of Science ®Google Scholar
• Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metabolism Reviews 2001; 33: 273–297
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry. 1994; 33: 1743–1752
   PubMed Web of Science ®Google Scholar
• Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metabolism and Disposition. 1997; 25: 598–602
   PubMed Web of Science ®Google Scholar
• Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems. British Journal of Clinical Pharmacology 1995; 40: 369–378
   PubMed Web of Science ®Google Scholar
• Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug–drug interactions. Pharmaceutical Research 2001; 18: 622–631
   PubMed Web of Science ®Google Scholar
• Knodell RG, Hall SD, Wilkinson GR, Guengerich FP. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. Journal of Pharmacology and Experimental Therapeutics 1987; 241: 1112–1119
   PubMed Web of Science ®Google Scholar
• Kobayashi F, Yageta Y, Segawa M, Matsuzawa S. Effects of imidafenacin (KRP-197/ONO-8025). 2007, a new anti-cholinergic agent, on muscarinic acetylcholine receptors — high affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 57 (in press)
   Google Scholar
• Kronbach T. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods in Enzymology 1991; 206: 509–517
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods in Enzymology 1996; 272: 139–145
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology 1998; 45: 525–538
   PubMed Web of Science ®Google Scholar
• Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Pharmacology 1988; 37: 1137–1144
   Google Scholar
• Miyachi H, Kiyota H, Segawa M. Novel imidazole derivatives with subtype-selective antimuscarinic activity (1). Bioorganic and Medicinal Chemistry Letters 1998a; 8: 1807–1812
   PubMed Web of Science ®Google Scholar
• Miyachi H, Kiyota H, Segawa M. Novel imidazole derivatives with subtype-selective antimuscarinic activity (2). Bioorganic and Medicinal Chemistry Letters 1998b; 8: 2163–2168
   PubMed Web of Science ®Google Scholar
• Miyachi H, Kiyota H, Segawa M. Design, synthesis and antimuscarinic activity of some imidazolium derivatives. Bioorganic and Medicinal Chemistry Letters 1999a; 9: 3003–3008
   PubMed Web of Science ®Google Scholar
• Miyachi H, Kiyota H, Uchiki H, Segawa M. Synthesis and antimuscarinic activity of a series of 4-(1-imidazoyl)-2,2-diphenylbutyramides: Discovery of potent and subtype-selective antimuscarinic agents. Bioorganic and Medicinal Chemistry 1999b; 7: 1151–1161
   PubMed Web of Science ®Google Scholar
• Murakami S, Yoshida M, Iwashita H, Otani M, Miyamae K, Masunaga K, Miyamoto Y, Inadome A, Ueda S. Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urologia Internationalis 2003; 71: 290–298
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nakada S, Miyata Y. Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy volunteers. Drug Metabolism Reviews 2005; 37(Suppl. 2)134
   Google Scholar
• Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ, Satoh T. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996; 26: 1155–1166
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 1552–1562
   PubMed Web of Science ®Google Scholar
• Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chemical Research in Toxicology 1990; 3: 566–573
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Dwyer LM, Cribb AE. (+)-Bufuralol 1′-hydroxylation activity in human and rhesus monkey intestine and liver. Biochemical Pharmacology 1995; 50: 1521–1525
   PubMed Web of Science ®Google Scholar
• Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metabolism Reviews 2002; 34: 83–448
   PubMed Web of Science ®Google Scholar
• Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. British Journal of Clinical Pharmacology 1996; 41: 181–186
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstetrics and Gynecology 2000; 95: 718–721
   PubMed Web of Science ®Google Scholar
• Weaver RJ. Assessment of drug–drug interactions: Concepts and approaches. Xenobiotica 2001; 31: 499–538
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, Shimada T. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Molecular Pharmacology 1994; 46: 568–577
   PubMed Web of Science ®Google Scholar